Table 2 Summary of clinical endpoints.
From: Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
Characteristic | Dapagliflozin group (n = 89) | Metformin group (n = 82) | Dapagliflozin plus metformin group (n = 77) |
|---|---|---|---|
∆Body weight (kg) | − 3.7 (0.8) | − 3.6 (0.7) | − 6.9 (0.9)*# |
∆BMI (kg/m2) | − 1.0 (0.1) | − 1.0 (0.1) | − 1.7 (0.1)*# |
∆Waist circumference (cm) | − 3.1 (1.0) | − 3.0 (0.8) | − 4.7 (0.9)*# |
∆Systolic blood pressure (mmHg) | − 3.4 (1.0)∮ | − 1.1 (0.8) | − 4.2 (0.9)# |
∆Diastolic blood pressure (mmHg) | − 2.0 (1.0)∮ | − 0.6 (0.1) | − 2.9 (0.9)# |
∆Fasting plasma glucose (mmol/L) | − 1.2 (0.1) | − 1.0 (0.1) | − 2.3 (0.2)*# |
∆Fasting plasma insulin (mIU/L) | − 1.0 (0.8) | − 1.2 (0.8) | − 2.5 (1.1)*# |
∆HOMA-IR | − 1.5 (1.3) | − 1.4 (1.1) | − 3.1 (1.2)*# |
∆HbA1c (%) | − 0.8 (0.1) | − 0.8 (0.2) | − 1.3 (0.2)*# |
∆HDL cholesterol (mmol/L) | 0.05 (0.01) | 0.04 (0.01) | 0.10 (0.02)*# |
∆LDL cholesterol (mmol/L) | 0.07 (0.01) | 0.06 (0.01) | 0.08 (0.01) |
∆Triglycerides (mmol/L) | − 0.69 (0.03) | − 0.86 (0.02) | − 1.9 (0.04)*# |
∆hsCRP (mg/L) | − 1.0 (0.6) | − 1.2 (0.8) | − 2.5 (1.0)*# |
∆PMN/HDL-C | − 0.02 (0.02) | − 0.01 (0.02) | − 0.06 (0.02)*# |
∆Monocytes/HDL-C | − 0.03 (0.04) | − 0.04 (0.04) | − 0.09 (0.03)*# |
Patients with remitting metabolic syndrome, n (%) | 41 (46.1%) | 47 (57.3%) | 59 (76.6%)*# |
